Korean Diabetes J.  2009 Oct;33(5):363-372. 10.4093/kdj.2009.33.5.363.

Clinical Implications of Serum Biomarkers in Diabetic Cardiovascular Complications

• Son JW
• Kwon HS

• KMID: 2231142
• DOI: http://doi.org/10.4093/kdj.2009.33.5.363

Abstract

Diabetes is associated with increased risk of cardiovascular disease, with atherosclerosis responsible for most associated morbidity and mortality. Atherosclerosis often causes acute thrombotic events through plaque rupture and formation of platelet-rich thrombi. The principal clinical manifestations of atherosclerosis are coronary artery disease, ischemic stroke, and peripheral arterial disease. Endothelial dysfunction, oxidative stress, and low-grade inflammation are key features in the pathophysiology of atherosclerosis.

Keyword

Atherosclerosis; Biological markers; Cardiovascular disease; Diabetes mellitus

MeSH Terms

Atherosclerosis
Biomarkers
Cardiovascular Diseases
Coronary Artery Disease
Diabetes Mellitus
Inflammation
Oxidative Stress
Peripheral Arterial Disease
Rupture
Stroke

Figure

• 

  Fig. 1 An inflammatory pathway links risk factors to altered cellular behavior and elevated inflammatory markers in peripheral blood. (Adapted from reference 4)

Reference

1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998. 21:1138–1145.

2. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diabetes Vasc Dis Res. 2007. 4:84–88.

3. Hadi A, Jassim A. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007. 3:853–876.

4. Libby P, Ridker PM. Inflammation and atherothrombosis - from population biology and bench research to clinical practice. J Am Coll Cardiol. 2006. 48:suppl 1. A33–A46.

5. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999. 100:1134–1146.

6. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-Reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004. 27:889–894.

7. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-Sensitivity C-Reactive protein and coronary heart disease mortality in patients with type 2 diabetes. Diabetes Care. 2006. 29:329–333.

8. Ferri N, Paoletti R, Corsini A. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Curr Opin Lipidol. 2006. 17:495–501.

9. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002. 51:1157–1165.

10. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: The Hoorn Study. Arterioscler Thromb Vasc Biol. 2006. 26:1086–1093.

11. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the atherosclerosis risk in communities (ARIC) study. Ann Intern Med. 2000. 133:81–91.

12. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med. 2004. 140:94–100.

13. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, Schernthaner G. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis. 2006. 189:236–240.

14. Yamada T. Serum amyloid A (SAA): a concise review of biology, assays methods and clinical usefulness. cance. Clin Chem Lab Med. 1999. 37:381–388.

15. Hamano M, Saito M, Eto M, Nishimatsu S, Suda H, Matsuda M, Matsuki M, Yamamoto S, Kaku K. Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease. Ann Clin Biochem. 2004. 41:125–129.

16. Li-Saw-Hee FL, Edmunds E, Blann A, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol. 2000. 75:43–47.

17. Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase genes. Methods Mol Biol. 2001. 151:121–148.

18. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, Cicero AF. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels. 2007. 22:361–370.

19. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005. 353:46–57.

20. Weinbrenner T, Cladellas M, Isabel Covas M, Fito M, Tomas M, Senti M. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis. 2003. 168:99–106.

21. Stephens JW, Gable DR, Hurel SJ, Miller GJ, Cooper JA, Humphries SE. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem. 2006. 52:446–452.

22. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003. 370:1097–1109.

23. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis. Diabetes Care. 2009. 32:1218–1220.

24. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with Type 2 Diabetes. Mol med. 2007. 13:185–189.

25. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis. 2009. 204:288–292.

26. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999. 99:224–229.

27. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care. 2002. 25:537–541.

28. Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J, Epstein SE. Antibodies to human heatshock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation. 2001. 103:1071–1075.

29. Zhu J, Quyyumi AA, Wu H, Csako G, Rott D, Zalles-Ganley A, Ogunmakinwa J, Halcox J, Epstein SE. Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arterioscler Thromb Vasc Biol. 2003. 23:1055–1059.

30. Gruden G, Bruno G, Chaturvedi N, Burt D, Pinach S, Schalkwijk C, Stehouwer CD, Witte DR, Fuller JH, Cavallo-Perin P. EURODIAB Prospective Complications Study Group. ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/macrovascular complications in type 1 diabetes:the EURODIAB Study. J Intern Med. 2009. 05. 08. [Epub ahead of print].

31. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997. 272:32401–32410.

32. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007. 27:916–922.

33. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 2008. 199:440–444.

34. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB. Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes. Diabetes. 2008. 57:2762–2767.

35. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A. Plasma Fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008. 118:2555–2562.

36. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991. 22:312–318.

37. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke. 1998. 29:2491–2500.

38. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001. 154:635–641.

39. Kanai A, Kawamura T, Umemura T, Nagashima M, Nakamura N, Nakayama M, Sano T, Nakashima E, Hamada Y, Nakamura J, Hotta N. Association between future events of brain infarction and soluble levels of intercellular adhesion molecule-1 and C-reactive protein in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008. 82:157–164.

40. Kawamura T, Umemura T, Kanai A, Nagashima M, Nakamura N, Uno T, Nakayama M, Sano T, Hamada Y, Nakamura J, Hotta N. Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism. 2006. 55:461–466.

41. Tsukahara T, Nakashima E, Watarai A, Hamada Y, Naruse K, Kamiya H, Nakamura N, Kato N, Hamajima N, Sekido Y, Niwa T, Tomita M, Oiso Y, Nakamura J. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009. 84:179–186.

42. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006. 47:921–929.

43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.

44. Fung ET, Wilson AM, Zhang F, Harris N, Edwards KA, Olin JW, Cooke JP. A biomarker panel for peripheral arterial disease. Vasc Med. 2008. 13:217–224.

45. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY, Zhang F, Beck KR, Olin JW, Fung ET, Cooke JP. β2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation. 2007. 116:1396–1403.

46. Sahli D, Eriksson JW, Boman K, Svensson MK. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thromb Res. 2009. 123:701–706.

47. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 2007. 30:670–676.

48. Celentano A, Vaccaro O, Tammaro P, Galderisi M, Crivaro M, Oliviero M, Imperatore G, Palmieri V, Iovino V, Riccardi G, Divitiis O. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol. 1995. 76:1173–1176.

49. Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, Reaven PD. VADT. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis. 2009. 203:610–614.

50. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004. 89:3872–3878.

51. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 2005. 54:345–350.

52. Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M. Serum Cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes. 2007. 56:2774–2779.

53. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001. 69:89–95.

54. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006. 355:2631–2639.

55. Ware JH. The Limitations of Risk Factors as Prognostic Tools. N Engl J med. 2006. 355:2615–2617.

56. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature. 2008. 451:949–952.

57. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A, Liu PP. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006. 48:1733–1741.

58. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001. 104:1280–1285.

59. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002. 105:2766–2771.

60. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with α_vβ₃-integrin-targeted nanoparticles. Circulation. 2003. 108:2270–2274.